General Toxicity Notes
Myelosuppressive and may aggravate uremic predisposition to hemorrhage and infection.
Excreted Unchanged %
No data
Half-Life (Normalesrd) Hours
1.5/No data
Plasma Protein Binding %
No data
Volume Of Distribution L/Kg
3.3
Dose For Normal Renal Function
150-200 mg/m2
Adjustment For Renal Failure Method
D
Adjustment For Renal Failure Gfr, Ml/Min >50 [Recommended Level]
No data [D]
Adjustment For Renal Failure Gfr, Ml/Min 10-50 [Recommended Level]
No data [D]
Adjustment For Renal Failure Gfr, Ml/Min <10 [Recommended Level]
Avoid [D]
Supplement For Dialysis [Recommendation Level]: Ihd
IHD: Avoid, [D]
Supplement For Dialysis [Recommendation Level]: Pd
PD: Avoid, [D]
Supplement For Dialysis [Recommendation Level]: Crrt
CRRT: No data
References
Black DJ, Livingston RB. Antineoplastic drugs in 1990. A review (Part I). Drugs. 1990; 39: 489-501. [PMID: 2190792] / Muggia FM, Von Hoff DD. In: Speight TM, Holford N, eds. Avery’ s Drug Treatment, 4th ed. Auckland: ADIS International; 1997: 1255.